Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

These weight management drugs, which mimic natural hormones that regulate insulin and glucose levels, have become increasingly popular due to their effectiveness in promoting weight loss. However, ...

This may start to bring down the cost of brand-name competitors—here's who might get access, and one major difference from ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its ...

The fight against type 2 diabetes just reached a groundbreaking milestone. Last week, the U.S. Food and Drug Administration ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

Treatment with GLP-1RAs was associated with significant improvements in obstructive sleep apnea-related health outcomes.